Adrenoleukodystrophy: survey of 303 cases: biochemistry, diagnosis, and therapy.

Adrenoleukodystrophy (ALD) is a genetically determined disorder associated with progressive central demyelination and adrenal cortical insufficiency.
All affected persons show increased levels of saturated unbranched very-long-chain fatty acids, particularly hexacosanoate (C26  0), because of impaired capacity to degrade these acids.
This degradation normally takes place in a subcellular organelle called the peroxisome, and ALD, together with Zellwegers cerebrohepatorenal syndrome, is now considered to belong to the newly formed category of peroxisomal disorders.
Biochemical assays permit prenatal diagnosis, as well as identification of most heterozygotes.
We have identified 303 patients with ALD in 217 kindreds.
These patients show a wide phenotypic variation.
Sixty percent of patients had childhood ALD and 17% adrenomyeloneuropathy, both of which are X-linked, with the gene mapped to Xq28. Neonatal ALD, a distinct entity with autosomal recessive inheritance and points of resemblance to Zellwegers syndrome, accounted for 7% of the cases.
Although excess C26  0 in the brain of patients with ALD is partially of dietary origin, dietary C26  0 restriction did not produce clear benefit.
Bone marrow transplant lowered the plasma C26  0 level but failed to arrest neurological progression.. 
